Roles of interleukin6 in occurrence, development and prognosis of hepatocellular carcinoma

doi:10.3760/cma.j.issn.1673-422X.2017.10.016

Abstract

Abstract: Interleukin6 (IL6) involves in a variety of inflammatory responses and immune regulation, showing closely correlations to tumor progression. Recent studies reveal that IL6 may play an important role in constituting tumor microenvironment, activating related signal pathway, regulating downstream transcription factors, to affect the proliferation, invasion and metastasis of tumor cells. IL6 has important potential value in the targeted therapy for hepatocellular carcinoma.

Key words: Liver neoplasms, Prognosis, Interleukin6

Zhang Bin, Shi Dongmei, Qiao Sen. Roles of interleukin6 in occurrence, development and prognosis of hepatocellular carcinoma[J]. Journal of International Oncology, 2017, 44(10): 787-789.

References

［1］ Gravitz L. liver cancer［J］. Nature, 2014, 516(7529): S1. DOI: 10.1038/516S1a. ［2］ Hirano T. Revisiting the 1986 molecular cloning of interleukin 6［J］. Front Immunol, 2014, 5: 456. DOI: 10.3389/fimmu.2014.00456. ［3］ He G, Dhar D, Nakagawa H, et al. Identification of liver cancer progenitors whose malignant progression depends on autorine IL6 signaling［J］. Cell, 2013, 155(2): 384396. DOI: 10.1016/j.cell.2013.09.031. ［4］ Tian G, Mi J, Wei X, et al. Circulating interleukin6 and cancer: a metaanalysis using Mendelian randomization［J］. Sci Rep, 2015, 5: 11394. DOI: 10.1038/srep11394. ［5］ Zhu CP, Wang AQ, Zhang HH, et al. Research progress and prospects of markers for liver cancer stem cells［J］. World J Gastroenterol, 2015, 21(42): 1219012196. DOI: 10.3748/wjg.v21.i42.12190. ［6］吴林, 宦宏波, 吴黎雳, 等. 炎症因子与肝癌干细胞标志在肝癌诱导过程中的相关性研究［J］. 实用临床医药杂志, 2014, 18(7): 16. DOI: 10.7619/jcmp.201407001. ［7］ Piperi C, Samaras V, Levidou G, et al. Prognostic significance of IL8STAT3 pathway in astrocytomas: correlation with IL6, VEGF and microvessel morphometry［J］. Cytokine, 2011, 55(3): 387395. DOI: 10.1016/j.cyto.2011.05.012. ［8］ Matsumura A, Kubota T, Taiyoh H, et al. HGF regulates VEGF expression via the cMet receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells［J］. Int J Oncol, 2013, 42(2): 535542. DOI: 10.3892/ijo.2012.1728. ［9］ Stahl A, Joyal JS, Chen J, et al. SOCS3 is an endogenous inhibitor of pathologic angiogenesis［J］. Blood, 2012, 120(14): 29252929. DOI: 10.1182/blood201204422527. ［10］ Rhee YH, Jeong SJ, Lee HJ, et al. Inhibition of STAT3 signaling and induction of SHP1 mediate antiangiogenic and antitumor activities of ergosterol peroxide in U266 multiple myeloma cells［J］. BMC Cancer, 2012, 12: 28. DOI: 10.1186/147124071228. ［11］ Zhao XL, Sun T, Che N, et al. Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelialmesenchymal transition regulator Twist1［J］. J Cell Mol Med, 2011, 15(3): 691700. DOI: 10.1111/j.15824934.2010.01052.x. ［12］ Cho KH, Jeong KJ, Shin SC, et al. STAT3 mediates TGFβ1induced TWIST1 expression and prostate cancer invasion［J］. Cancer Lett, 2013, 336(1): 167173. DOI: 10.1016/j.canlet.2013.04.024. ［13］ Yang L, Hou Y, Yuan J, et al. Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways［J］. Oncotarget, 2015, 6(28): 2575525769. DOI: 10.18632/oncotarget.4697. ［14］ So KA, Min KJ, Hong JH, et al. Interleukin6 expression by interactions between gynecologic cancer cells and human mesenchymal stem cells promotes epithelialmesenchymal transition［J］. Int J Oncol, 2015, 47(4): 14511459. DOI: 10.3892/ijo.2015.3122. ［15］ Wang CQ, Sun HT, Gao XM, et al. Interleukin6 enhances cancer stemness and promotes metastasis of hepatocellular carcinoma via upregulating osteopontin expression［J］. Am J Cancer Res, 2016, 6(9): 18731889. ［16］ Ghaffari A, Hoskin V, Szeto A, et al. A novel role for ezrin in breast cancer angio/lymphangiogenesis［J］. Breast Cancer Res, 2014, 16(5): 438. DOI: 10.1186/s1305801404382. ［17］张斌, 钟德玝, 王群伟, 等. JAK/STAT信号通路与肝细胞性肝癌的肿瘤进展和预后的相关性研究［J］. 细胞与分子免疫学杂志, 2010, 26(4): 368373. DOI: 10.13423/j.cnki.cjcmi.005452. ［18］ Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma［J］. Lancet, 2012, 379(9822): 12451255. ［19］ Zhao WC, Fan LF, Yang N, et al. Preoperative predictors of microvascular invasion in multinodular hepatocellular carcinoma［J］. Eur J Surg Oncol, 2013, 39(8): 858864. DOI: 10.1016/j.ejso.2013.04.003. ［20］ Sheng T, Wang B, Wang SY, et al. The relationship between serum interleukin6 and the recurrence of hepatitis B virus related hepatocellular carcinoma after curative resection［J］. Medicine (Baltimore), 2015, 94(24): e941. DOI: 10.1097/MD.0000000000000941. ［21］ Ghoshal S, Fuchs BC, Tanabe KK, et al. STAT3 is a key transcriptional regulator of cancer stem cell marker CD133 in HCC［J］. Hepatobiliary Surg Nutr, 2016, 5(3): 201203. DOI: 10.21037/hbsn.2016.03.02. ［22］ Hur W, Ryu JY, Kim HU, et al. Systems approach to characterize the metabolism of liver cancer stem cells expressing CD133［J］. Sci Rep, 2017, 7: 45557. DOI: 10.1038/srep45557. ［23］ Korkaya H, Kim GI, Davis A, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population［J］. Mol Cell, 2012, 47(4): 570584. DOI: 10.1016/j.molcel.2012.06.014. ［24］ Martin del Campo SE, Levine KM, MundyBosse BL, et al. The Raf kinase inhibitor sorafenib inhibits JAKSTAT signal transduction in human immune cells［J］. J Immunol, 2015, 195(5): 19952005. DOI: 10.4049/jimmunol.1400084.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[6]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[7]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[8]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[9]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[10]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[11]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[12]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[13]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[14]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[15]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.